Lunch with Emergent Medical Consultants

Track: Networking

Session Number: 62
Date: Fri, Apr 13th, 2018
Time: 11:30 AM - 12:30 PM
Room: Banquet Foyer


For over 50 years, the only widely available anticoagulant available for the reduction of stroke in patients with atrial fibrillation was the vitamin K antagonist Warfarin. That medication was also used for the outpatient management of DVT and PE. Beginning in 2010, the anticoagulant landscape exploded with new medications including both the direct thrombin inhibitor (Pradaxa) as well as the Factor Xa Inhibitors (Xarelto, Eliquis, Sayvasa and Betrixiban) all entering the market with variable indications. Some of these medications are used in patients with atrial fibrillation while others are used for DVT, PE. In addition, some of these new medicines are used in patients with coronary artery disease, peripheral artery disease, orthopedic prophylaxis and even home thrombus prevention after discharge from the inpatient setting.

These medications have specific med-med interactions as well as contraindications. In addition, these may not be the only medications that are associated with increased risk of bleeding that a patient takes since many patients also take an antiplatelet or NSAID. Which patients are appropriate for these medications and which should not be on these medicines? What type of bleeding is expected if the correct patients are selected for the medications? What are the pitfalls with use of the medicines? How do we reverse emergent bleeding events? Should we be using the medications if there are no reversal agents? Is there still a role for Coumadin?

Over the course of the lunch talk, Dr. Wilson will provide an introduction to this class of medicines and begin to answer the questions outlined above. Attendees will understand how patient selection for specific medications is made and what type of errors he sees with these medications in his experiences as a research director studying anticoagulation with involvement in numerous clinical trials, an attending emergency medicine physician that manages these types of bleed, and an experienced expert witness that reviews cases associated with bleed management.
Session Type: N/A

Session Type: N/A